Transplantation & Clinical Virology, Department Biomedicine, University of Basel, Basel, Switzerland.
Swiss Transplant Cohort Study, University Hospital Basel, Basel, Switzerland.
Am J Transplant. 2017 Oct;17(10):2591-2600. doi: 10.1111/ajt.14282. Epub 2017 Apr 25.
BK polyomavirus (BKPyV) causes premature kidney transplant (KT) failure in 1-15% of patients. Because antivirals are lacking, most programs screen for BKPyV-viremia and, if positive, reduce immunosuppression. To evaluate the relationship of viremia and BKPyV-specific immunity, we examined prospectively cryopreserved plasma and peripheral blood mononuclear cells at the time of transplantation (T0) and at 6 mo (T6) and 12 mo (T12) after transplant from 28 viremic KT patients and 68 nonviremic controls matched for the transplantation period. BKPyV IgG seroprevalence was comparable between cases (89.3%) and controls (91.2%; p = 0.8635), but cases had lower antibody levels (p = 0.022) at T0. Antibody levels increased at T6 and T12 but were not correlated with viremia clearance. BKPyV-specific T cell responses to pools of overlapping 15mers (15mer peptide pool [15mP]) or immunodominant CD8 9mers (9mer peptide pool [9mP]) from the early viral gene region were not different between cases and controls at T0; however, clearance of viremia was associated with stronger 9mP responses at T6 (p = 0.042) and T12 (p = 0.048), whereas 15mP responses were not informative (T6 p = 0.359; T12 p = 0.856). BKPyV-specific T cells could be expanded in vitro from all patients after transplant, permitting identification of 78 immunodominant 9mer epitopes including 50 new ones across different HLA class I. Thus, 9mP-responses may be a novel marker of reconstituting CD8 T cell function that warrants further study as a complement of plasma BKPyV loads for guiding immunosuppression reduction.
BK 多瘤病毒(BKPyV)可导致 1-15%的患者出现早期肾移植(KT)失败。由于缺乏抗病毒药物,大多数方案都对 BKPyV 病毒血症进行筛查,如果呈阳性,则减少免疫抑制。为了评估病毒血症与 BKPyV 特异性免疫之间的关系,我们前瞻性地检测了 28 例病毒血症 KT 患者和 68 例同期非病毒血症对照者在移植时(T0)、移植后 6 个月(T6)和 12 个月(T12)的冷冻保存血浆和外周血单个核细胞。病例组(89.3%)和对照组(91.2%)的 BKPyV IgG 血清阳性率无差异(p = 0.8635),但病例组在 T0 时的抗体水平较低(p = 0.022)。抗体水平在 T6 和 T12 时增加,但与病毒血症清除无关。T0 时,病例组和对照组对早期病毒基因区的重叠 15mer 池(15mer 肽池[15mP])或免疫优势 CD8 9mer 池(9mer 肽池[9mP])的 BKPyV 特异性 T 细胞反应无差异;然而,病毒血症清除与 T6(p = 0.042)和 T12(p = 0.048)时更强的 9mP 反应相关,而 15mP 反应无信息(T6 p = 0.359;T12 p = 0.856)。移植后,所有患者均可从外周血中体外扩增 BKPyV 特异性 T 细胞,鉴定出 78 个免疫优势的 9mer 表位,包括不同 HLA Ⅰ类中的 50 个新表位。因此,9mP 反应可能是重建 CD8 T 细胞功能的新型标志物,值得进一步研究,作为指导免疫抑制减少的血浆 BKPyV 负荷的补充。